Robert W. Baird Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price

Boston Scientific (NYSE:BSX) had its target price decreased by Robert W. Baird from $118.00 to $101.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird’s target price points to a potential upside of 33.77% from the company’s previous close.

BSX has been the topic of a number of other reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, January 21st. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Royal Bank Of Canada upped their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Morgan Stanley boosted their price target on Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $115.75.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $75.50 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific has a 1-year low of $75.00 and a 1-year high of $109.50. The company has a market capitalization of $111.92 billion, a price-to-earnings ratio of 40.37, a PEG ratio of 1.63 and a beta of 0.67. The business has a 50-day moving average of $94.37 and a 200-day moving average of $99.13.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s revenue was up 15.9% on a year-over-year basis. During the same period last year, the business posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts anticipate that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors have recently bought and sold shares of BSX. Riverwater Partners LLC boosted its holdings in shares of Boston Scientific by 3.3% in the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after buying an additional 98 shares during the period. Gerber Kawasaki Wealth & Investment Management lifted its position in shares of Boston Scientific by 3.8% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after acquiring an additional 99 shares in the last quarter. Crown Wealth Group LLC lifted its position in shares of Boston Scientific by 4.7% in the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after acquiring an additional 100 shares in the last quarter. Claret Asset Management Corp boosted its stake in Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 102 shares during the period. Finally, Sound View Wealth Advisors Group LLC grew its position in Boston Scientific by 3.9% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 103 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS of $0.80 and $5.29B in revenue with ~16% reported sales growth and margin improvement, confirming underlying top‑line momentum. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Operational growth and beat on consensus EPS give the company credibility that core businesses are expanding, supporting longer‑term revenue prospects. Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates
• Neutral Sentiment: Wall Street still has a majority of buy ratings and an above‑current consensus price target, suggesting analysts may be cautious but not uniform in selling. MarketBeat BSX profile
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS and revenue ranges came in modest and slightly below consensus in places, and Q1 guidance was cautious — this trimmed near‑term growth expectations and triggered the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology and a key hyped device underperformed expectations, prompting concern that some growth drivers will be weaker than modeled. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Market reaction amplified by heavy bearish activity and a sharp intraday drop (including a 52‑week/18‑month low); options flow showed a surge in put buying, signaling short‑term bearish positioning. BSX Earnings: Boston Scientific Stock (BSX) Plunges 17% on Weak Guidance
• Negative Sentiment: Large insider sale disclosed (CEO sold ~160,901 shares), which may add to investor nervousness despite the company’s fundamentals. SEC filing: Insider sale by Michael Mahoney

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.